ATE260662T1 - Verwendung von olanzapin zur herstellung eines arzneimittels zur neuroprotektion - Google Patents

Verwendung von olanzapin zur herstellung eines arzneimittels zur neuroprotektion

Info

Publication number
ATE260662T1
ATE260662T1 AT01202986T AT01202986T ATE260662T1 AT E260662 T1 ATE260662 T1 AT E260662T1 AT 01202986 T AT01202986 T AT 01202986T AT 01202986 T AT01202986 T AT 01202986T AT E260662 T1 ATE260662 T1 AT E260662T1
Authority
AT
Austria
Prior art keywords
olanzapine
neuroprotection
production
medicinal product
neuro
Prior art date
Application number
AT01202986T
Other languages
English (en)
Inventor
Franklin Bymaster
Gary Dennis Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE260662T1 publication Critical patent/ATE260662T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT01202986T 1997-04-15 1998-04-09 Verwendung von olanzapin zur herstellung eines arzneimittels zur neuroprotektion ATE260662T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4309497P 1997-04-15 1997-04-15

Publications (1)

Publication Number Publication Date
ATE260662T1 true ATE260662T1 (de) 2004-03-15

Family

ID=21925472

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98302789T ATE213945T1 (de) 1997-04-15 1998-04-09 Verwendung von olanzapin zur herstellung eines arzneimittels zur neuroprotektion
AT01202986T ATE260662T1 (de) 1997-04-15 1998-04-09 Verwendung von olanzapin zur herstellung eines arzneimittels zur neuroprotektion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98302789T ATE213945T1 (de) 1997-04-15 1998-04-09 Verwendung von olanzapin zur herstellung eines arzneimittels zur neuroprotektion

Country Status (8)

Country Link
EP (1) EP0872238B1 (de)
AT (2) ATE213945T1 (de)
AU (1) AU6955998A (de)
DE (2) DE69804034T2 (de)
DK (1) DK0872238T3 (de)
ES (2) ES2215851T3 (de)
PT (2) PT872238E (de)
WO (1) WO1998046596A1 (de)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US5627178A (en) * 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal
US5744470A (en) * 1996-03-11 1998-04-28 Eli Lilly And Company Method for treating insomnia
US5744469A (en) * 1996-11-26 1998-04-28 Eli Lilly And Company Method for treating dermatitis

Also Published As

Publication number Publication date
EP0872238A2 (de) 1998-10-21
DE69804034D1 (de) 2002-04-11
WO1998046596A1 (en) 1998-10-22
DE69804034T2 (de) 2002-10-17
AU6955998A (en) 1998-11-11
ATE213945T1 (de) 2002-03-15
PT1155696E (pt) 2004-06-30
PT872238E (pt) 2002-07-31
DK0872238T3 (da) 2002-06-24
EP0872238B1 (de) 2002-03-06
DE69822234D1 (de) 2004-04-08
ES2215851T3 (es) 2004-10-16
ES2173550T3 (es) 2002-10-16
EP0872238A3 (de) 1998-10-28
DE69822234T2 (de) 2005-02-24

Similar Documents

Publication Publication Date Title
DE69204639D1 (de) Verwendung von Modafinil zur Herstellung eines antiischämischen Arzneimittels.
DE69435330D1 (de) Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
EP1139746A4 (de) Verbindungen und verfahren zur behandlung von atemwegserkrankungen sowie zur verabreichung von arzneistoffen für die atmewege
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE220923T1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
IL114296A (en) Use of melatonin in the manufacture of medicament for treating or preventing addiction to benzodiazepines pharmaceutical formulation for this purpose and process for making the formulation
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
NO944339L (no) Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser
DE59611383D1 (de) Darreichungsform zur applikation von pharmazeutischen wirkstoffen und hilfsstoffen und verfahren zur herstellung derselben
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
ATE136465T1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
ATE260662T1 (de) Verwendung von olanzapin zur herstellung eines arzneimittels zur neuroprotektion
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
ATA14996A (de) Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
ITMI941939A0 (it) Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1155696

Country of ref document: EP

REN Ceased due to non-payment of the annual fee